
Tullio Florio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3542138/publications.pdf Version: 2024-02-01



Τιμμο Ειοριο

#	Article	IF	CITATIONS
1	Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives. Journal of Experimental and Clinical Cancer Research, 2022, 41, 53.	8.6	15
2	Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?. Journal of Clinical Medicine, 2022, 11, 1019.	2.4	5
3	Metformin antitumoral activity is exclusively mediated by the membrane functional expression of the chloride intracellular channel 1 in glioblastoma stem cells. , 2022, , .		0
4	An Overview of Long Non-Coding (Inc)RNAs in Neuroblastoma. International Journal of Molecular Sciences, 2021, 22, 4234.	4.1	8
5	Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects. Cancers, 2021, 13, 1816.	3.7	5
6	Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?. Frontiers in Endocrinology, 2021, 12, 667784.	3.5	13
7	Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice. International Journal of Molecular Sciences, 2021, 22, 6753.	4.1	4
8	Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. Frontiers in Endocrinology, 2021, 12, 700806.	3.5	2
9	Two Novel PET Radiopharmaceuticals for Endothelial Vascular Cell Adhesion Molecule-1 (VCAM-1) Targeting. Pharmaceutics, 2021, 13, 1025.	4.5	18
10	N6-Isopentenyladenosine Hinders the Vasculogenic Mimicry in Human Glioblastoma Cells through Src-120 Catenin Pathway Modulation and RhoA Activity Inhibition. International Journal of Molecular Sciences, 2021, 22, 10530.	4.1	5
11	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /C	Overlock 10	Tf 50 342
12	Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. Journal of Clinical Medicine, 2021, 10, 88.	2.4	19
13	Structure and Properties of Electrochemically Synthesized Silver Nanoparticles in Aqueous Solution by High-Resolution Techniques. Molecules, 2021, 26, .	3.8	1
14	Structure and Properties of Electrochemically Synthesized Silver Nanoparticles in Aqueous Solution by High-Resolution Techniques. Molecules, 2021, 26, 5155.	3.8	4
15	Exosomes and Extracellular Vesicles as Emerging Theranostic Platforms in Cancer Research. Cells, 2020, 9, 2569.	4.1	46
16	Co-Administration of Fendiline Hydrochloride Enhances Chemotherapeutic Efficacy of Cisplatin in Neuroblastoma Treatment. Molecules, 2020, 25, 5234.	3.8	6
17	MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment. Biomedicines, 2020, 8, 471.	3.2	9
18	Identification of the hydantoin alkaloids parazoanthines as novel CXCR4 antagonists by computational and in vitro functional characterization. Bioorganic Chemistry, 2020, 105, 104337.	4.1	4

#	Article	IF	CITATIONS
19	Extracellular Vesicles Loaded miRNAs as Potential Modulators Shared Between Glioblastoma, and Parkinson's and Alzheimer's Diseases. Frontiers in Cellular Neuroscience, 2020, 14, 590034.	3.7	13
20	Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies. Stem Cells Translational Medicine, 2020, 9, 1310-1330.	3.3	28
21	Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells. Frontiers in Endocrinology, 2020, 11, 54.	3.5	22
22	Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity. Molecular Neurobiology, 2019, 56, 1957-1971.	4.0	13
23	Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. International Journal of Molecular Sciences, 2019, 20, 3940.	4.1	26
24	Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells. Cancers, 2019, 11, 747.	3.7	36
25	Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity. Frontiers in Oncology, 2019, 9, 135.	2.8	21
26	Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity. International Journal of Molecular Sciences, 2019, 20, 901.	4.1	81
27	Proteases Upregulation in Sporadic Alzheimer's Disease Brain. Journal of Alzheimer's Disease, 2019, 68, 931-938.	2.6	12
28	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	3.0	15
29	Emerging Role of Cellular Prion Protein in the Maintenance and Expansion of Glioma Stem Cells. Cells, 2019, 8, 1458.	4.1	11
30	Abstract 2549: Allostatic conditions in human glioblastoma stem cells are maintained with the contribution of CLIC1 membrane protein functional expression. , 2019, , .		0
31	Abstract 2549: Allostatic conditions in human glioblastoma stem cells are maintained with the contribution of CLIC1 membrane protein functional expression. , 2019, , .		0
32	<i>In Silico</i> Identification and Experimental Validation of Novel Anti-Alzheimer's Multitargeted Ligands from a Marine Source Featuring a "2-Aminoimidazole plus Aromatic Group―Scaffold. ACS Chemical Neuroscience, 2018, 9, 1290-1303.	3.5	14
33	Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects. Scientific Reports, 2018, 8, 3929.	3.3	24
34	Sprouty2 enhances the tumorigenic potential of glioblastoma cells. Neuro-Oncology, 2018, 20, 1044-1054.	1.2	28
35	Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death. Cell Death and Disease, 2018, 9, 166.	6.3	38
36	In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity. Experimental Cell Research, 2018, 363, 48-64.	2.6	30

#	Article	IF	CITATIONS
37	Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability. Frontiers in Pharmacology, 2018, 9, 899.	3.5	30
38	Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocrine-Related Cancer, 2018, 25, R453-R466.	3.1	39
39	Mutual Influence of ROS, pH, and CLIC1 Membrane Protein in the Regulation of G1–S Phase Progression in Human Glioblastoma Stem Cells. Molecular Cancer Therapeutics, 2018, 17, 2451-2461.	4.1	21
40	Primary Cultures from Human GH-secreting or Clinically Non-functioning Pituitary Adenomas. Bio-protocol, 2018, 8, e2790.	0.4	1
41	Abstract 4299: Mutual influence of ROS, pH and CLIC1 membrane protein in the regulation of G1/S phase progression in human glioblastoma stem cells. , 2018, , .		0
42	Different Molecular Mechanisms Mediate Direct or Glia-Dependent Prion Protein Fragment 90–231 Neurotoxic Effects in Cerebellar Granule Neurons. Neurotoxicity Research, 2017, 32, 381-397.	2.7	5
43	The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. Stem Cell Research and Therapy, 2017, 8, 119.	5.5	21
44	Complexity and Selectivity of γ-Secretase Cleavage on Multiple Substrates: Consequences in Alzheimer's Disease and Cancer. Journal of Alzheimer's Disease, 2017, 61, 1-15.	2.6	17
45	Does pasireotide directly modulate skeletal muscle metabolism?. Endocrine, 2017, 57, 6-8.	2.3	2
46	Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors. Endocrine, 2017, 57, 214-219.	2.3	81
47	Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas. Molecular Neurobiology, 2017, 54, 4879-4895.	4.0	57
48	Different Effects of Human Umbilical Cord Mesenchymal Stem Cells on Glioblastoma Stem Cells by Direct Cell Interaction or Via Released Soluble Factors. Frontiers in Cellular Neuroscience, 2017, 11, 312.	3.7	51
49	Abstract 304: CLIC1 membrane insertion is a pivotal regulator of glioblastoma stem cell G1-S transition by promoting an increase of chloride permeability. , 2017, , .		2
50	The inhibition of 45A ncRNA expression reduces tumor formation, affecting tumor nodules compactness and metastatic potential in neuroblastoma cells. Oncotarget, 2017, 8, 8189-8205.	1.8	11
51	A novel splice variant of the protein tyrosine phosphatase <i>PTPRJ</i> that encodes for a soluble protein involved in angiogenesis. Oncotarget, 2017, 8, 10091-10102.	1.8	8
52	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. Oncotarget, 2017, 8, 41044-41063.	1.8	24
53	PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs. PPAR Research, 2016, 2016, 1-10.	2.4	16
54	Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells. Frontiers in Molecular Neuroscience, 2016, 9, 107.	2.9	37

Tullio Florio

#	Article	IF	CITATIONS
55	Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma. Expert Opinion on Drug Discovery, 2016, 11, 1093-1109.	5.0	28
56	Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide. Pharmacological Research, 2016, 113, 500-514.	7.1	22
57	Down-regulation of 21A Alu RNA as a tool to boost proliferation maintaining the tissue regeneration potential of progenitor cells. Cell Cycle, 2016, 15, 2420-2430.	2.6	3
58	Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA. Scientific Reports, 2016, 5, 18144.	3.3	38
59	A critical concentration of N-terminal pyroglutamylated amyloid beta drives the misfolding of Ab1-42 into more toxic aggregates. International Journal of Biochemistry and Cell Biology, 2016, 79, 261-270.	2.8	44
60	FGFR4 Polymorphism as Molecular Determinant of the Efficacy of mTOR Inhibitors In GH-Secreting Pituitary Adenomas. Endocrinology, 2016, 157, 3400-3401.	2.8	1
61	Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells. Molecular Neurobiology, 2016, 53, 57-72.	4.0	25
62	Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discovery Today, 2016, 21, 190-199.	6.4	117
63	SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. Oncotarget, 2016, 7, 15868-15884.	1.8	54
64	Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells. Oncotarget, 2016, 7, 38638-38657.	1.8	53
65	Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies. Current Drug Targets, 2016, 17, 824-849.	2.1	12
66	Subventricular zone microenvironment protects glioblastoma cells from radiotherapy cytotoxicity: role of the chemokine CXCL12. Translational Cancer Research, 2016, 5, S1098-S1101.	1.0	0
67	Canine osteosarcoma cell lines contain stem-like cancer cells: biological and pharmacological characterization. Japanese Journal of Veterinary Research, 2016, 64, 101-12.	0.7	4
68	Ruta graveolens L. Induces Death of Glioblastoma Cells and Neural Progenitors, but Not of Neurons, via ERK 1/2 and AKT Activation. PLoS ONE, 2015, 10, e0118864.	2.5	37
69	Chloride channels in cancer: Focus on chloride intracellular channel 1 and 4 (CLIC1 AND CLIC4) proteins in tumor development and as novel therapeutic targets. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2523-2531.	2.6	130
70	In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer, 2015, 15, 228.	2.6	47
71	The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle, 2015, 14, 3418-3429.	2.6	104
72	New Molecules and Old Drugs as Emerging Approaches to Selectively Target Human Glioblastoma Cancer Stem Cells. BioMed Research International, 2014, 2014, 1-11.	1.9	59

#	Article	IF	CITATIONS
73	CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Frontiers in Cellular Neuroscience, 2014, 8, 144.	3.7	129
74	Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. International Journal of Endocrinology, 2014, 2014, 1-16.	1.5	18
75	Adult Pituitary Stem Cells. Pancreatic Islet Biology, 2014, , 91-109.	0.3	1
76	Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA. Cancer Cell International, 2014, 14, 59.	4.1	30
77	Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discovery Today, 2014, 19, 458-468.	6.4	31
78	Adiponectin as Novel Regulator of Cell Proliferation in Human Glioblastoma. Journal of Cellular Physiology, 2014, 229, 1444-1454.	4.1	26
79	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocrine-Related Cancer, 2014, 21, 691-704.	3.1	53
80	Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. Oncotarget, 2014, 5, 11252-11268.	1.8	108
81	An intronic ncRNA-dependent regulation of SORL1 expression affecting Aβ formation is upregulated in <i>post-mortem</i> Alzheimer's disease brain samples. DMM Disease Models and Mechanisms, 2013, 6, 424-33.	2.4	131
82	EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene, 2013, 32, 2670-2681.	5.9	106
83	Excitotoxicity Through NMDA Receptors Mediates Cerebellar Granule Neuron Apoptosis Induced by Prion Protein 90-231 Fragment. Neurotoxicity Research, 2013, 23, 301-314.	2.7	21
84	Minimalist Hybrid Ligand/Receptor-Based Pharmacophore Model for CXCR4 Applied to a Small-Library of Marine Natural Products Led to the Identification of Phidianidine A as a New CXCR4 Ligand Exhibiting Antagonist Activity. ACS Chemical Biology, 2013, 8, 2762-2770.	3.4	54
85	Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology, 2013, 314, 209-220.	4.2	95
86	A novel snRNA-like transcript affects amyloidogenesis and cell cycle progression through perturbation of Fe65L1 (APBB2) alternative splicing. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1511-1526.	4.1	18
87	Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle, 2013, 12, 491-500.	2.6	64
88	Metformin selectively affects human glioblastoma tumor-initiating cell viability. Cell Cycle, 2013, 12, 145-156.	2.6	154
89	Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm. International Journal of Peptides, 2013, 2013, 1-20.	0.7	102
90	Neuroblastoma: Inhibition by Alu-Like RNA. Pediatric Cancer, 2013, , 57-66.	0.0	0

#	Article	IF	CITATIONS
91	A Novel Collection of snRNA-Like Promoters with Tissue-Specific Transcription Properties. International Journal of Molecular Sciences, 2012, 13, 11323-11332.	4.1	6
92	Role of Prion Protein Aggregation in Neurotoxicity. International Journal of Molecular Sciences, 2012, 13, 8648-8669.	4.1	37
93	Recombinant Human Prion Protein Fragment 90–231, a Useful Model to Study Prion Neurotoxicity. OMICS A Journal of Integrative Biology, 2012, 16, 50-59.	2.0	9
94	Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. British Journal of Pharmacology, 2012, 166, 532-553.	5.4	19
95	In vitro study of uptake and synthesis of creatine and its precursors by cerebellar granule cells and astrocytes suggests some hypotheses on the physiopathology of the inherited disorders of creatine metabolism. BMC Neuroscience, 2012, 13, 41.	1.9	17
96	CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis. BMC Veterinary Research, 2012, 8, 27.	1.9	16
97	Tryptophan hydroxylase 2 (<scp>TPH</scp> 2) in a neuronal cell line: modulation by cell differentiation and <scp>NRSF</scp> /rest activity. Journal of Neurochemistry, 2012, 123, 963-970.	3.9	28
98	Differential toxicity, conformation and morphology of typical initial aggregation states of Aβ1-42 and Aβpy3-42 beta-amyloids. International Journal of Biochemistry and Cell Biology, 2012, 44, 2085-2093.	2.8	44
99	The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells. Drug Discovery Today, 2012, 17, 1103-1110.	6.4	48
100	Calcium Binding Promotes Prion Protein Fragment 90–231 Conformational Change toward a Membrane Destabilizing and Cytotoxic Structure. PLoS ONE, 2012, 7, e38314.	2.5	14
101	Neurodegeneration in Alzheimer Disease: Role of Amyloid Precursor Protein and Presenilin 1 Intracellular Signaling. Journal of Toxicology, 2012, 2012, 1-13.	3.0	56
102	Amyloid-β Protein Precursor Regulates Phosphorylation and Cellular Compartmentalization of Microtubule Associated Protein Tau. Journal of Alzheimer's Disease, 2012, 29, 211-227.	2.6	19
103	Balance between somatostatin and D2 receptor expression drives TSHâ€secreting adenoma response to somatostatin analogues and dopastatins. Clinical Endocrinology, 2012, 76, 407-414.	2.4	47
104	NDM29, a RNA polymerase III-dependent non coding RNA, promotes amyloidogenic processing of APP and amyloid β secretion. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 1170-1177.	4.1	100
105	Goat antiâ€human <scp>GM</scp> â€ <scp>CSF</scp> recognizes canine <scp>GM</scp> â€ <scp>CSF</scp> . Veterinary Clinical Pathology, 2012, 41, 3-4.	0.7	2
106	Isolation of stem-like cells from spontaneous feline mammary carcinomas: Phenotypic characterization and tumorigenic potential. Experimental Cell Research, 2012, 318, 847-860.	2.6	25
107	Abstract 10: Oncogenic variant EGFRvIII defines a hierarchy in glioblastoma and expression is restricted by epigenetic mechanisms despite the presence of gene amplification. , 2012, , .		0
108	High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein. International Journal of Biochemistry and Cell Biology, 2011, 43, 372-382.	2.8	33

#	Article	IF	CITATIONS
109	The pathological prion protein forms ionic conductance in lipid bilayer. Neurochemistry International, 2011, 59, 168-174.	3.8	17
110	Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma. Trends in Pharmacological Sciences, 2011, 32, 463-479.	8.7	21
111	Persistent increase of d-aspartate in d-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay. Neurobiology of Aging, 2011, 32, 2061-2074.	3.1	60
112	Somatostatin receptor 1,2 and 5 activation leads to C6 glioma growth arrest in vitro and in vivo; analysis of the intracellular pathways involved. Journal of Biological Research (Italy), 2011, 84, .	0.1	0
113	An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease. Haematologica, 2011, 96, 1015-1023.	3.5	37
114	17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease. Neurobiology of Disease, 2011, 41, 308-317.	4.4	199
115	Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature. Journal of Neuroimmunology, 2011, 234, 115-123.	2.3	33
116	Chemokines and chemokine receptors: New actors in neuroendocrine regulations. Frontiers in Neuroendocrinology, 2011, 32, 10-24.	5.2	79
117	Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets. Biochemical Pharmacology, 2011, 82, 1467-1477.	4.4	18
118	In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary, 2011, 14, 141-147.	2.9	40
119	Efficacy of Novel Acridine Derivatives in the Inhibition of hPrP90-231 Prion Protein Fragment Toxicity. Neurotoxicity Research, 2011, 19, 556-574.	2.7	31
120	Human PrP90-231-induced cell death is associated with intracellular accumulation of insoluble and protease-resistant macroaggregates and lysosomal dysfunction. Cell Death and Disease, 2011, 2, e138-e138.	6.3	30
121	Adult Pituitary Stem Cells: From Pituitary Plasticity to Adenoma Development. Neuroendocrinology, 2011, 94, 265-277.	2.5	54
122	The Chemokine SDF1/CXCL12: A Novel Autocrine/Paracrine Factor Involved In Pituitary Adenoma Development. Open Neuroendocrinology Journal (Online), 2011, 4, 64-76.	0.4	11
123	Glioblastoma Cancer Stem Cells: Response to Epidermal Growth Factor Receptor Kinase Inhibitors. , 2011, , 213-226.		Ο
124	Molecular mechanisms mediating the neuroproyective effects of quinacrine and minocycline on cell death induced by the prion protein fragment 90-231 (hPrP90-231). Journal of Biological Research (Italy), 2011, 84, .	0.1	0
125	Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation. Current Cancer Drug Targets, 2010, 10, 176-191.	1.6	21
126	Role of Chemokine Network in the Development and Progression of Ovarian Cancer: A Potential Novel Pharmacological Target. Journal of Oncology, 2010, 2010, 1-15.	1.3	65

#	Article	IF	CITATIONS
127	An Aluâ€like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells. FASEB Journal, 2010, 24, 4033-4046.	0.5	71
128	The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells. Cancer Research, 2010, 70, 666-674.	0.9	93
129	The Eighth Fibronectin Type III Domain of Protein Tyrosine Phosphatase Receptor J Influences the Formation of Protein Complexes and Cell Localization. Journal of Biochemistry, 2009, 145, 377-385.	1.7	15
130	Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors. Journal of Biological Chemistry, 2009, 284, 7138-7148.	3.4	117
131	Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E1078-E1088.	3.5	24
132	Dual Modulation of ERK1/2 and p38 MAP Kinase Activities Induced by Minocycline Reverses the Neurotoxic Effects of the Prion Protein Fragment 90–231. Neurotoxicity Research, 2009, 15, 138-154.	2.7	31
133	Protective Effects of Some Creatine Derivatives in Brain Tissue Anoxia. Neurochemical Research, 2008, 33, 765-775.	3.3	28
134	Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Frontiers in Bioscience - Landmark, 2008, 13, 806.	3.0	146
135	Somatostatin inhibits colon cancer cell growth through cyclooxygenaseâ€2 downregulation. British Journal of Pharmacology, 2008, 155, 198-209.	5.4	31
136	Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatases. Molecular and Cellular Endocrinology, 2008, 286, 40-48.	3.2	70
137	Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-Related Cancer, 2008, 15, 583-596.	3.1	93
138	17β-Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment. Molecular Pharmacology, 2008, 73, 191-202.	2.3	68
139	Overexpression of Stromal Cell–Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas. Clinical Cancer Research, 2008, 14, 5022-5032.	7.0	104
140	Somatostatin Receptors 1, 2, and 5 Cooperate in the Somatostatin Inhibition of C6 Glioma Cell Proliferation in Vitro via a Phosphotyrosine Phosphatase-ÎDependent Inhibition of Extracellularly Regulated Kinase-1/2. Endocrinology, 2008, 149, 4736-4746.	2.8	47
141	Chemokines, their Receptors and Significance in Brain Function. NeuroImmune Biology, 2008, , 242-273.	0.2	4
142	Amyloid Precursor Protein and Presenilin1 Interact with the Adaptor GRB2 and Modulate ERK 1,2 Signaling. Journal of Biological Chemistry, 2007, 282, 13833-13844.	3.4	83
143	Role of stromal cell-derived factor 1 (SDF1/CXCL12) in regulating anterior pituitary function. Journal of Molecular Endocrinology, 2007, 38, 383-389.	2.5	42
144	Amyloid Precursor Protein and Presenilin Involvement in Cell Signaling. Neurodegenerative Diseases, 2007, 4, 101-111.	1.4	15

#	Article	IF	CITATIONS
145	An Intracellular Multi-Effector Complex Mediates Somatostatin Receptor 1 Activation of Phospho-Tyrosine Phosphatase η. Molecular Endocrinology, 2007, 21, 229-246.	3.7	22
146	CXCR4 and SDF1 expression in human meningiomas: A proliferative role in tumoral meningothelial cells in vitro1. Neuro-Oncology, 2007, 9, 3-11.	1.2	53
147	ERK1/2 and p38 MAP kinases control prion protein fragment 90–231â€induced astrocyte proliferation and microglia activation. Glia, 2007, 55, 1469-1485.	4.9	32
148	Different structural stability and toxicity of PrPARRand PrPARQsheep prion protein variants. Journal of Neurochemistry, 2007, 103, 2291-2300.	3.9	16
149	Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90–231, as possible mechanism of its neurotoxic effects. Journal of Neurochemistry, 2007, 103, 071018045431007-???.	3.9	27
150	Amyloid Precursor Protein and Presenilin 1 Interaction Studied by FRET in Human H4 Cells. Annals of the New York Academy of Sciences, 2007, 1096, 249-257.	3.8	15
151	Amino-Terminally Truncated Prion Protein PrP90-231 Induces Microglial Activation in Vitro. Annals of the New York Academy of Sciences, 2007, 1096, 258-270.	3.8	15
152	Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract. Amino Acids, 2007, 32, 395-400.	2.7	9
153	Octreotide, a Somatostatin Analogue, Mediates Its Antiproliferative Action in Pituitary Tumor Cells by Altering Phosphatidylinositol 3-Kinase Signaling and Inducing Zac1 Expression. Cancer Research, 2006, 66, 1576-1582.	0.9	197
154	Expression of CXC chemokine receptors 1–5 and their ligands in human glioma tissues: Role of CXCR4 and SDF1 in glioma cell proliferation and migration. Neurochemistry International, 2006, 49, 423-432.	3.8	144
155	The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds. Neuroscience, 2006, 142, 991-997.	2.3	47
156	Conformation Dependent Pro-Apoptotic Activity of the Recombinant Human Prion Protein Fragment 90-231. International Journal of Immunopathology and Pharmacology, 2006, 19, 339-356.	2.1	30
157	Pattern of Distribution of Calcitonin Gene-Related Peptide in the Dorsal Root Ganglion of Animal Models of Diabetes Mellitus. Annals of the New York Academy of Sciences, 2006, 1084, 296-303.	3.8	15
158	CXC Receptor and Chemokine Expression in Human Meningioma: SDF1/CXCR4 Signaling Activates ERK1/2 and Stimulates Meningioma Cell Proliferation. Annals of the New York Academy of Sciences, 2006, 1090, 332-343.	3.8	38
159	SDF-1 Controls Pituitary Cell Proliferation through the Activation of ERK1/2 and the Ca2+-Dependent, Cytosolic Tyrosine Kinase Pyk2. Annals of the New York Academy of Sciences, 2006, 1090, 385-398.	3.8	33
160	Amyloid Precursor Protein Modulates ERK-1 and -2 Signaling. Annals of the New York Academy of Sciences, 2006, 1090, 455-465.	3.8	17
161	Chemokine Stromal Cell-Derived Factor 1α Induces Proliferation and Growth Hormone Release in GH4C1 Rat Pituitary Adenoma Cell Line through Multiple Intracellular Signals. Molecular Pharmacology, 2006, 69, 539-546.	2.3	49
162	Characterization of the Proapoptotic Intracellular Mechanisms Induced by a Toxic Conformer of the Recombinant Human Prion Protein Fragment 90-231. Annals of the New York Academy of Sciences, 2006, 1090, 276-291.	3.8	15

#	Article	IF	CITATIONS
163	Identification of a Conserved N-Capping Box Important for the Structural Autonomy of the Prion α3-Helix: The Disease Associated D202N Mutation Destabilizes the Helical Conformation. International Journal of Immunopathology and Pharmacology, 2005, 18, 95-112.	2.1	41
164	The rat tyrosine phosphatase \hat{I} increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. Oncogene, 2005, 24, 3187-3195.	5.9	48
165	Somatostatin Receptor Subtype-Dependent Regulation of Nitric Oxide Release: Involvement of Different Intracellular Pathways. Molecular Endocrinology, 2005, 19, 255-267.	3.7	44
166	Stromal cell-derived factor-1α (SDF-1α/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Experimental Cell Research, 2005, 308, 241-253.	2.6	153
167	Molecular Mechanisms Mediating Neuronal Cell Death in Experimental Models of Prion Diseases, in vitro. , 2005, , 273-297.		0
168	The Expression of the Phosphotyrosine Phosphatase DEP-1/PTPη Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation. Journal of Biological Chemistry, 2004, 279, 29004-29012.	3.4	55
169	Expression of Somatostatin Receptor mRNA in Human Meningiomas and their Implication in in vitro Antiproliferative Activity. Journal of Neuro-Oncology, 2004, 66, 155-166.	2.9	87
170	The Phosphotyrosine Phosphatase η Mediates Somatostatin Inhibition of Glioma Proliferation via the Dephosphorylation of ERK1/2. Annals of the New York Academy of Sciences, 2004, 1030, 264-274.	3.8	33
171	Prion Protein Fragment 106-126 Induces a p38 MAP Kinase-Dependent Apoptosis in SH-SY5Y Neuroblastoma Cells Independently from the Amyloid Fibril Formation. Annals of the New York Academy of Sciences, 2003, 1010, 610-622.	3.8	47
172	Contribution of two conserved glycine residues to fibrillogenesis of the 106–126 prion protein fragment. Evidence that a soluble variant of the 106–126 peptide is neurotoxic. Journal of Neurochemistry, 2003, 85, 62-72.	3.9	60
173	Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clinical Endocrinology, 2003, 59, 115-128.	2.4	48
174	Chemokines and their receptors in the CNS: expression of CXCL12/SDF-1 and CXCR4 and their role in astrocyte proliferation. Toxicology Letters, 2003, 139, 181-189.	0.8	88
175	Pyrrolidinedithiocarbamate induces apoptosis in cerebellar granule cells: involvement of AP-1 and MAP kinases. Neurochemistry International, 2003, 43, 31-38.	3.8	13
176	Somatostatin Inhibits Tumor Angiogenesis and Growth via Somatostatin Receptor-3-Mediated Regulation of Endothelial Nitric Oxide Synthase and Mitogen-Activated Protein Kinase Activities. Endocrinology, 2003, 144, 1574-1584.	2.8	160
177	The Tyrosine Phosphatase Shp-2 Mediates Intracellular Signaling Initiated by Ret Mutants. Endocrinology, 2003, 144, 4298-4305.	2.8	14
178	Basic Fibroblast Growth Factor Activates Endothelial Nitric-Oxide Synthase in CHO-K1 Cells via the Activation of Ceramide Synthesis. Molecular Pharmacology, 2003, 63, 297-310.	2.3	32
179	Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Research, 2003, 63, 1969-74.	0.9	272
180	In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors. Anticancer Research, 2003, 23, 2465-71.	1.1	14

#	Article	IF	CITATIONS
181	p38 MAP Kinase Mediates the Cell Death Induced by PrP106–126 in the SH-SY5Y Neuroblastoma Cells. Neurobiology of Disease, 2002, 9, 69-81.	4.4	59
182	Expression in E. coli and purification of recombinant fragments of wild type and mutant human prion protein. Neurochemistry International, 2002, 41, 55-63.	3.8	31
183	Isolation of a Long-Lasting <i>eag</i> -Related Gene-Type K ⁺ Current in MMQ Lactotrophs and Its Accommodating Role during Slow Firing and Prolactin Release. Journal of Neuroscience, 2002, 22, 3414-3425.	3.6	38
184	<i>InÂvitro</i> effect of human recombinant leptin and expression of leptin receptors on growth hormoneâ€secreting human pituitary adenomas. Clinical Endocrinology, 2002, 57, 449-455.	2.4	25
185	Expression of the Chemokine Receptor CXCR4 and Its Ligand Stromal Cellâ€Derived Factor 1 in Human Brain Tumors and Their Involvement in Glial Proliferation <i>in Vitro</i> . Annals of the New York Academy of Sciences, 2002, 973, 60-69.	3.8	97
186	Nitric Oxide Production Stimulated by the Basic Fibroblast Growth Factor Requires the Synthesis of Ceramide. Annals of the New York Academy of Sciences, 2002, 973, 94-104.	3.8	12
187	Proteasome Inhibitors Induce Cerebellar Granule Cell Death. Annals of the New York Academy of Sciences, 2002, 973, 402-413.	3.8	19
188	Stromal cellâ€derived factorâ€1α induces astrocyte proliferation through the activation of extracellular signalâ€regulated kinases 1/2 pathway. Journal of Neurochemistry, 2001, 77, 1226-1236.	3.9	177
189	Inhibition of nuclear factor-?B activation induces apoptosis in cerebellar granule cells. Journal of Neuroscience Research, 2001, 66, 1064-1073.	2.9	51
190	Purine nucleosides protect injured neurons and stimulate neuronal regeneration by intracellular and membrane receptor-mediated mechanisms. Drug Development Research, 2001, 52, 303-315.	2.9	25
191	Chemokines and Their Receptors in the Central Nervous System. Frontiers in Neuroendocrinology, 2001, 22, 147-184.	5.2	348
192	The Activation of the Phosphotyrosine Phosphatase η (r-PTPη) Is Responsible for the Somatostatin Inhibition of PC Cl3 Thyroid Cell Proliferation. Molecular Endocrinology, 2001, 15, 1838-1852.	3.7	49
193	The Activation of the Phosphotyrosine Phosphatase (r-PTPÂ) Is Responsible for the Somatostatin Inhibition of PC Cl3 Thyroid Cell Proliferation. Molecular Endocrinology, 2001, 15, 1838-1852.	3.7	29
194	Cultured astrocyte proliferation induced by extracellular guanosine involves endogenous adenosine and is raised by the co-presence of microglia. , 2000, 29, 202-211.		89
195	Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. Journal of Physiology (Paris), 2000, 94, 239-250.	2.1	56
196	Apoptotic Cell Death and Impairment of L-Type Voltage-Sensitive Calcium Channel Activity in Rat Cerebellar Granule Cells Treated with the Prion Protein Fragment 106–126. Neurobiology of Disease, 2000, 7, 299-309.	4.4	64
197	Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106–126. International Journal of Developmental Neuroscience, 2000, 18, 481-492.	1.6	56
198	Cabergoline modulation of α-subunits and FSH secretion in a gonadotroph adenoma. Journal of Endocrinological Investigation, 2000, 23, 463-466.	3.3	20

#	Article	IF	CITATIONS
199	Cultured astrocyte proliferation induced by extracellular guanosine involves endogenous adenosine and is raised by the co-presence of microglia. Glia, 2000, 29, 202.	4.9	3
200	Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB Journal, 1999, 13, 647-655.	0.5	101
201	Somatostatin Activation of Mitogen-Activated Protein Kinase via Somatostatin Receptor 1 (SSTR1). Molecular Endocrinology, 1999, 13, 24-37.	3.7	121
202	A novel mechanism for the melatonin inhibition of testosterone secretion by rat Leydig cells: reduction of GnRH-induced increase in cytosolic Ca2+. Journal of Molecular Endocrinology, 1999, 23, 299-306.	2.5	32
203	Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology, 1999, 141, 396-408.	3.7	75
204	Expression of Chemokine Receptors in the Rat Brain ^a . Annals of the New York Academy of Sciences, 1999, 876, 201-209.	3.8	68
205	Prolonged treatment with α-glycerylphosphorylethanolamine facilitates the acquisition of an active avoidance behavior and selectively increases neuronal signal transduction in rats. Aging Clinical and Experimental Research, 1999, 11, 335-342.	2.9	2
206	Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: Involvement of A2 purinergic receptor subtypes. Life Sciences, 1999, 64, 1661-1674.	4.3	74
207	Glial and Neuronal Cells Express Functional Chemokine Receptor CXCR4 and Its Natural Ligand Stromal Cellâ€Derived Factor 1. Journal of Neurochemistry, 1999, 73, 2348-2357.	3.9	197
208	Somatostatin Activation of Mitogen-Activated Protein Kinase via Somatostatin Receptor 1 (SSTR1). Molecular Endocrinology, 1999, 13, 24-37.	3.7	48
209	Intracellular Signalling Mediating HIV-1 gp120 Neurotoxicity. Cellular Signalling, 1998, 10, 75-84.	3.6	22
210	Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line. , 1998, 54, 341-352.		73
211	Oncogene Transformation of PC Cl3 Clonal Thyroid Cell Line Induces an Autonomous Pattern of Proliferation That Correlates with a Loss of Basal and Stimulated Phosphotyrosine Phosphatase Activity*. Endocrinology, 1997, 138, 3756-3763.	2.8	19
212	Somatostatin Inhibits Interleukin 6 Release from Rat Cortical Type I Astrocytes via the Inhibition of Adenylyl Cyclase. Biochemical and Biophysical Research Communications, 1997, 235, 242-248.	2.1	31
213	TGF-?1 prevents gp120-induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death. , 1997, 49, 600-607.		47
214	Oncogene Transformation of PC Cl3 Clonal Thyroid Cell Line Induces an Autonomous Pattern of Proliferation That Correlates with a Loss of Basal and Stimulated Phosphotyrosine Phosphatase Activity. Endocrinology, 1997, 138, 3756-3763.	2.8	9
215	Intracellular Calcium Rise through L-Type Calcium Channels, as Molecular Mechanism for Prion Protein Fragment 106-126-Induced Astroglial Proliferation. Biochemical and Biophysical Research Communications, 1996, 228, 397-405.	2.1	76
216	INTRACELLULAR TRANSDUCING MECHANISMS COUPLED TO BRAIN SOMATOSTATIN RECEPTORS. Pharmacological Research, 1996, 33, 297-305.	7.1	12

#	Article	IF	CITATIONS
217	Somatostatin Inhibits PC Cl3 Thyroid Cell Proliferation through the Modulation of Phosphotyrosine Phosphatase Activity. Journal of Biological Chemistry, 1996, 271, 6129-6136.	3.4	70
218	Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors. Journal of Molecular Endocrinology, 1996, 17, 89-100.	2.5	65
219	β25–35 Alters Calcium Homeostasis and Induces Neurotoxicity in Cerebellar Granule Cells. Journal of Neurochemistry, 1996, 66, 1995-2003.	3.9	38
220	Cyclic 3,5 adenoise monophosphate and cyclosporin A inhibit cellular proliferation and serine/threonine protein phosphatase activity in pituitary cells. Endocrinology, 1996, 137, 4409-4418.	2.8	3
221	A PRION PROTEIN FRAGMENT MODIFIES PLASMA MEMBRANE VISCOSITY AND INTRACELLULAR. CALCIUM LEVEL. Journal of Neuropathology and Experimental Neurology, 1995, 54, 449.	1.7	3
222	α1B, But Not α1A, Adrenoceptor Activates Calcium Influx through the Stimulation of a Tyrosine Kinase/Phosphotyrosine Phosphatase Pathway, Following Noradrenaline-Induced Emptying of IP3 Sensitive Calcium Stores, in PC C13 Rat Thyroid Cell Line. Biochemical and Biophysical Research Communications, 1995, 209, 630-638.	2.1	23
223	The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin- sensitive pathways. Endocrinology, 1994, 134, 1277-1285.	2.8	14
224	The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Molecular Endocrinology, 1994, 8, 1289-1297.	3.7	53
225	Effect of acetyl-?-carnitine treatment on brain adenylate cyclase activity in young and aged rats. European Neuropsychopharmacology, 1993, 3, 95-101.	0.7	2
226	G Protein Activation of a Hormone-Stimulated Phosphatase in Human Tumor Cells. Science, 1992, 256, 1215-1217.	12.6	214
227	Interleukin 6 modulation of second messenger systems in anterior pituitary cells. Life Sciences, 1992, 51, 1243-1248.	4.3	10
228	Modulation by GTP of Basal and Agonist-Stimulated Striatal Adenylate Cyclase Activity Following Chronic Blockade of D1 and D2 Dopamine Receptors: Involvement of G Proteins in the Development of Receptor Supersensitivity. Journal of Neurochemistry, 1992, 59, 1667-1674.	3.9	17
229	Molecular mechanisms mediating the effects of l-α-glycerylphosphorylcholine, a new cognition-enhancing drug, on behavioral and biochemical parameters in young and aged rats. Pharmacology Biochemistry and Behavior, 1992, 43, 139-151.	2.9	16
230	Dopamine and somatostatin inhibition of prolactin secretion from MMQ pituitary cells: role of adenosine triphosphate-sensitive potassium channels. Endocrinology, 1992, 131, 1942-1947.	2.8	9
231	Age-related alterations of somatostatin gene expression in different rat brain areas. Brain Research, 1991, 557, 64-68.	2.2	27
232	Dihydropyridine Modulation of Voltage-Activated Calcium Channels in PC12 Cells: Effect of Pertussis Toxin Pretreatment. Journal of Neurochemistry, 1991, 56, 805-811.	3.9	11
233	Interleukin-1-β Modulation of Prolactin Secretion from Rat Anterior Pituitary Cells: Involvement of Adenylate Cyclase Activity and Calcium Mobilization*. Endocrinology, 1990, 126, 1435-1441.	2.8	34
234	Adenosine and its analogue (â^')-N6-R-phenyl-isopropyladenosine modulate anterior pituitary adenylate cyclase activity and prolactin secretion in the rat. Journal of Molecular Endocrinology, 1990, 5, 69-76.	2.5	14

#	Article	IF	CITATIONS
235	Cytosolic calcium rise induced by maitotoxin in PC12 cells: Effect of omega-conotoxin (GVIA). Pharmacological Research, 1990, 22, 75-76.	7.1	2
236	Interleukin 1 beta modulation of TRH stimulated prolactin secretion and inositol phosphate production. Pharmacological Research, 1990, 22, 81-82.	7.1	0
237	Interleukin-1 Modulation of Anterior Pituitary Function Annals of the New York Academy of Sciences, 1990, 594, 489-491.	3.8	3
238	Fipexide improvement of cognitive functions in rat: Behavioural and neurochemical studies. Pharmacological Research, 1990, 22, 179-187.	7.1	6
239	Purinergic modulation of adenylate cyclase activity and prolactin secretion in rat adenohypophysis. European Journal of Pharmacology, 1990, 183, 483.	3.5	1
240	Interaction between immune and neuroendocrine systems: interleukin 1 beta inhibition of prolactin release and intracellular transducing mechanisms. European Journal of Pharmacology, 1990, 183, 2170.	3.5	0
241	Anterior pituitary adenosine receptors, coupled to adenylate cyclase, modulate prolactin release. Pharmacological Research, 1989, 21, 5-6.	7.1	0
242	Dihydropiridine inhibition of k+ and maitotoxin stimulated calcium fluxes in pc12 cells: effect of pertussis toxin. Pharmacological Research, 1989, 21, 1-2.	7.1	13
243	Interleukin I modulation of anterior pituitary function: Effect on hormone release and second messenger systems. Pharmacological Research, 1989, 21, 35-36.	7.1	5
244	Interleukin 1 beta inhibition of TRH-stimulated prolactin secretion and phosphoinositides metabolism. Biochemical and Biophysical Research Communications, 1989, 165, 496-505.	2.1	14
245	Somatostatin inhibition of adenylate cyclase activity in different brain areas. Brain Research, 1989, 492, 65-71.	2.2	72
246	Depletion of brain somatostatin (SRIF) by cysteamine (CSH) induces impairment of cognitive functions in rat: Reversal by administration of exogenous SRIF or its analogue SMS 201-995. Pharmacological Research Communications, 1988, 20, 241-242.	0.2	4
247	Dihydroergotoxin interaction with central dopaminergic neurotransmission. Pharmacological Research Communications, 1988, 20, 154.	0.2	0
248	Gonadectomy affects prolactin secretion from male and female rat lactotropes: A reverse hemolytic plaque assay study. Pharmacological Research Communications, 1988, 20, 200.	0.2	0
249	A pertussis toxin sensitive G protein mediates dihydropyridine inhibition of maitotoxin stimulated calcium flux in 235-1 pituitary clone. Pharmacological Research Communications, 1988, 20, 243.	0.2	2
250	Steroid modulation of prolactin release from single lactotropes in male and female rats studied by the reverse hemolytic plaque assay. Pharmacological Research Communications, 1988, 20, 1075-1076.	0.2	1
251	Role of G-proteins in mediating dihydropyridine receptor coupling with voltage sensitive calcium channels. Pharmacological Research Communications, 1988, 20, 1083-1084.	0.2	2
252	Pertussis toxin pretreatment abolishes dihydropyridine inhibition of calcium flux in the 235-1 pituitary cell line. Biochemical and Biophysical Research Communications, 1988, 151, 361-369.	2.1	10

Tullio Florio

#	Article	IF	CITATIONS
253	Somatostatin and SMS 201-995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatin. European Journal of Pharmacology, 1988, 151, 399-407.	3.5	48
254	Somatostatin inhibition of anterior pituitary adenylate cyclase activity: different sensitivity between male and female rats. Brain Research, 1988, 439, 322-329.	2.2	32
255	Effect of interleukin 1 beta on transducing mechanisms in 235-1 clonal pituitary cells. Biochemical and Biophysical Research Communications, 1988, 155, 1089-1096.	2.1	16
256	Effect of interleukin 1 beta on transducing mechanisms in 235-1 clonal pituitary cells. Biochemical and Biophysical Research Communications, 1988, 155, 1097-1104.	2.1	14
257	Calmodulin modulates prolactin secretion in vitro: Studies with calmodulin containing liposomes. Life Sciences, 1987, 41, 2437-2444.	4.3	5
258	Chemokines and pituitary functions. Frontiers in Neuroscience, 0, 3, .	2.8	0
259	Antitumoral effects of metformin on cancer stem cells: identification of novel molecular targets. Endocrine Abstracts, 0, , .	0.0	Ο